Agios Pharmaceuticals Inc (AGIO)

54.21
NASDAQ : Health Care
Prev Close 54.21
Day Low/High 0.00 / 0.00
52 Wk Low/High 33.50 / 81.77
Avg Volume 671.60K
Exchange NASDAQ
Shares Outstanding 38.05M
Market Cap 2.08B
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Agios Shares Spike on Planned Drug Application

Agios Shares Spike on Planned Drug Application

The drugmaker plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year.

Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene

Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene

Celgene owns the rights to the Agios drug known as AG-221 under an existing partnership.

Short Interest Increases 10.4% For AGIO

Short Interest Increases 10.4% For AGIO

The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 680,325 share increase in total short interest for Agios Pharmaceuticals Inc , to 7,219,945, an increase of 10.40% since 07/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Agios Pharmaceuticals (AGIO) Highlighted As Weak On High Volume

Agios Pharmaceuticals (AGIO) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Dr. Michael Rosenblatt Joins Flagship Ventures As Chief Medical Officer

Dr. Michael Rosenblatt Joins Flagship Ventures As Chief Medical Officer

New Position Created to Support Growing Clinical Research Programs Across Flagship's Start-up Ecosystem

Agios Pharmaceuticals (AGIO) Is Today's Dead Cat Bounce Stock

Agios Pharmaceuticals (AGIO) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a "dead cat bounce" (down big yesterday but up big today) candidate

Flagship Ventures Names Daniel McIntyre Partner

Flagship Ventures Names Daniel McIntyre Partner

Industry Veteran Assumes new position to lead strategic communication

AGIO Pharmacueticals (AGIO) Stock Up on Positive Drug Results

AGIO Pharmacueticals (AGIO) Stock Up on Positive Drug Results

AGIO Pharmacueticals (AGIO) announced positive results of it's anemia drug which led to an upgraded rating and increasing stock.

Trade-Ideas: Agios Pharmaceuticals (AGIO) Is Today's

Trade-Ideas: Agios Pharmaceuticals (AGIO) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a "dead cat bounce" (down big yesterday but up big today) candidate

Analysts' Actions -- Agios Pharma, Concho Resources, Occidental, Sprouts and More

Analysts' Actions -- Agios Pharma, Concho Resources, Occidental, Sprouts and More

Here are Monday's top research calls, including upgrades for Agios Pharmaceuticals and Concho Resources, and downgrades for Occidental Petroleum and Sprouts Farmers Market.

Agios Anemia Drug Data Hits the Mark and Raises Some Questions

Agios Anemia Drug Data Hits the Mark and Raises Some Questions

Agios Pharmaceuticals said its experimental drug AG-348 increased hemoglobin levels in nine of 18 patients with a rare, inherited form of anemia treated in a clinical trial.

Agios Pharmaceuticals (AGIO) Stock: Weak On High Volume Today

Agios Pharmaceuticals (AGIO) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate

Agios Pharmaceuticals (AGIO) Marked As A Dead Cat Bounce Stock

Agios Pharmaceuticals (AGIO) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a "dead cat bounce" (down big yesterday but up big today) candidate

Agios Pharmaceuticals (AGIO) Is Today's Perilous Reversal Stock

Agios Pharmaceuticals (AGIO) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a "perilous reversal" (up big yesterday but down big today) candidate

Agios Pharmaceuticals (AGIO) Weak On High Volume

Agios Pharmaceuticals (AGIO) Weak On High Volume

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate

Celgene, Agios Expand, Amend Cancer Drug Partnership

Celgene, Agios Expand, Amend Cancer Drug Partnership

Celgene is paying $200 million for development rights to early research Agios is conducting into new drug targets that alter the metabolism of immune cells to help kill cancer cells.

Agios Updates 2016 Financial Guidance

Agios Updates 2016 Financial Guidance